• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Adalimumab Product Approval Information - Licensing Action 12/31/02

Proper name: Adalimumab
Tradename: HUMIRA
Manufacturer: Abbott Laboratories, Abbott Park, IL, License #0043
Indication for Use: For reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be used alone or in combination with Methotrexate (MTX) or other DMARDs.
Approval Date: 12/31/2002
Type of submission: Biologics license application


Label (PDF)

Clinical Review - Part 5 (PDFs)

Chemistry Review (PDF)

Clinical Pharmacology and Biopharmaceutics Review (PDF)

Pharmacology Review (PDF)

Statistical Review (PDF)